SCHEMBL21467103

SCHEMBL21467103

Nc1ncnc2[nH]nc(-c3cc(O)ccc3Cl)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.40
PIK3CA P42336 13/20 0.40
PIK3CB P42338 13/20 0.40
PIK3CG P48736 13/20 0.40
PRKDC P78527 13/20 0.40
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
SRC P12931 13/20 0.36
ABL1 P00519 12/20 0.36
EGFR P00533 11/20 0.36
HCK P08631 10/20 0.36
KDR P35968 10/20 0.36
MTOR P42345 10/20 0.36
EPHB4 P54760 10/20 0.36
PI4KB Q9UBF8 9/20 0.36
PRKCA P17252 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11347 0.81 FGFR1 (0.44) SRCABL1EGFRHCKKDR
SCHEMBL21467104 0.78 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11325 0.77 PIK3CG (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20748491 0.76 PIK3CG (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11405 0.75 PIK3CG (0.61) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30386850 0.74 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL27774340 0.74 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL23917236 0.73 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL130525 0.73 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL3715031 0.71 SRC (0.57) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 PIK3CD 2/4885PIK3CA 4/4885PIK3CB 1/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3CA 144/4885PIK3CB 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.